Mitochondrial Pathway Signature (MitoPS) predicts immunotherapy response and reveals NDUFB10 as a key immune regulator in lung adenocarcinoma

Mitochondrial Pathway Signature (MitoPS) predicts immunotherapy response and reveals NDUFB10 as a key immune regulator in lung adenocarcinoma

Background Lung adenocarcinoma (LUAD) is the most common subtype of non-small cell lung cancer. Although immune checkpoint inhibitors (ICIs) have brought new treatment options for advanced patients, a considerable proportion still shows limited response. Mitochondrial dysfunction plays a crucial rol...

Full description

Saved in:
Bibliographic Details
Main Authors: Peng Luo, Zhenfa Zhang, Lianmin Zhang, Pengpeng Zhang, Mengzhe Zhang, Jianlan Liu, Zhaokai Zhou
Format: Article
Language:English
Published: BMJ Publishing Group 2025-07-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/13/7/e012069.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items